Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
US6706762B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 10, 1997 |
| Grant date | Mar 16, 2004 |
| Priority date | — |
| Expiry date | Nov 10, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/70567
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In accordance with the present invention, it has been discovered that histone deacetylase associates with hormone receptor complexes and contributes to the repression thereof. It has further been discovered that exposure of a repressed system to histone deacetylase inhibitors relieves this repression, and that in combination with a ligand for a member the steroid/thyroid superfamily of receptors, the differentiation effects of retinoids are enhanced. Thus, histone deacetylase inhibitors have been found to be useful for the activation of genes responsive to hormone receptors and to conteract the oncogenic functions of oncogenic proteins. In accordance with another aspect of the invention, formulations useful for modulation of hormone-mediated processes have been developed. In addition, assays have been developed for the identification of compounds useful to modulate the above-described processes as well as methods of employing such compounds for the treatment of neoplastic diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.